Dementia Improvement after Plasma Exchange for Familial Hypercholesterolemia by Allen J. Orehek

Get full text

Lipoprotein (a) levels in children with heterozygous familial hypercholesterolemia by Liliya F. Galimova, Dinara I. Sadykova, Evgeniia S. Slastnikova, Chulpan D. Khaliullina, Karina R. Salakhova

Subjects: Get full text

Case report of familial hypercholesterolemia with internal carotid neck swelling by Sudesh Kumar, Prajna Ray, Ranita Sahana

Subjects: Get full text

2024 Polish recommendations for the management of familial hypercholesterolemia in children and adolescents by Małgorzata Myśliwiec, Marta Bandura, Anna Wołoszyn-Durkiewicz, Matylda Hennig, Mieczysław Walczak, Jarosław Peregut-Pogorzelski, Jolanta Sykut-Cegielska, Maria Miszczak-Knecht, Krzysztof Chlebus, Bartosz Wasąg, Agnieszka Zmysłowska, Maciej Banach

Subjects: “…familial hypercholesterolemia…”
Get full text

Familial Hypercholesterolemia: Genetics, Symptoms, Diagnosis and Treatment - A Literature Overview by Maciej Rutkiewicz, Sabina Przygodzka, Katarzyna Gadżała, Karolina Garbino, Katarzyna Brudniak, Antoni Szuścik, Magdalena Czyczerska

Subjects: “…familial hypercholesterolemia…”
Get full text

Xantelasma Dan Arkus Kornea Juvenilis Sebagai Manifestasi Familial Hypercholesterolemia by Putrigusti Admira, Kemala Sayuti

“…Familial hypercholesterolemia (FH) merupakan kelainan dominan autosomal, disebabkan kelainan pada gen reseptor LDL (low density lipoprotein) di kromosom 19. …”
Get full text

Beyond identification of familial hypercholesterolemia: Improving downstream visits and treatments in a large health care system by Harin Lee, Tarun Kadaru, Ruth Schneider, Taylor Triana, Carol Tujardon, Colby Ayers, Mujeeb Basit, Zahid Ahmad, Amit Khera

Subjects: “…Familial hypercholesterolemia…”
Get full text

Development and implementation of a digiphysical screening model with nationwide reach to diagnose familial hypercholesterolemia by Karin Littmann, Gustav Kindborg, Matthias Lidin, Linda Mellbin, Daniel Eriksson Hogling, Jonas Brinck

“…Background Familial hypercholesterolemia (FH) is a hereditary dyslipidemia that confers a severely elevated risk for development of early atherosclerotic cardiovascular disease if left untreated. …”
Get full text

Liver transplantation for homozygous familial hypercholesterolemia: a retrospective analysis from Chinese experience by Hao-Su Zhan, Lin Wei, Wei Qu, Zhi-Gui Zeng, Ying Liu, Yu-Le Tan, Jun Wang, Liang Zhang, En-Hui He, Guang-Peng Zhou, Hai-Ming Zhang, Zhi-Jun Zhu, Li-Ying Sun

Subjects: “…Homozygous familial hypercholesterolemia…”
Get full text

Causal relationship of familial hypercholesterolemia with risk of intestinal vascular disorders: A mendelian randomization study by Gang Wei, Cheng Zhang, Feng-Jie Shen, Hua-Qi Guo, Lin Liu

Subjects: “…Familial hypercholesterolemia…”
Get full text

Marked Multiple Tendinitis at the Onset of Rheumatoid Arthritis in a Patient with Heterozygous Familial Hypercholesterolemia: Ultrasonographic Observation by Takeshi Suzuki, Akiko Okamoto

“…A 59-year-old woman who had been diagnosed with heterozygous familial hypercholesterolemia developed rheumatoid arthritis (RA). …”
Get full text

Searching for new genes associated with the familial hypercholesterolemia phenotype using whole-genome sequencing and machine learning by D. E. Ivanoshchuk, A. B. Kolker, O. V. Timoshchenko, S. E. Semaev, E. V. Shakhtshneider

Subjects: “…familial hypercholesterolemia…”
Get full text

Analysis of the low density lipoprotein receptor gene (<i>LDLR</i>) mutation spectrum in Russian familial hypercholesterolemia by V. B. Vasilyev, F. M. Zakharova, T. Yu. Bogoslovskaya, M. Yu. Mandelshtam

Subjects: “…familial hypercholesterolemia…”
Get full text

ApoB100 remodeling and stiffened cholesteryl ester core raise LDL aggregation in familial hypercholesterolemia patients by Maria Teresa La Chica Lhoëst, Andrea Martínez, Eduardo Garcia, Jany Dandurand, Anna Polishchuk, Aleyda Benitez-Amaro, Ana Cenarro, Fernando Civeira, Amable Bernabé, David Vilades, Joan Carles Escolà-Gil, Valerie Samouillan, Vicenta Llorente-Cortes

“…Patients with familial hypercholesterolemia (FH) exhibit a significant residual cardiovascular risk. …”
Get full text

A strategy to increase identification of patients with Familial Hypercholesterolemia: Application of the Simon Broome lipid criteria in a large-scale retrospective analysis by James K. Fleming, Renee M. Sullivan, David Alfego, Natalia T. Leach, Tamara J. Richman, Jill Rafalko

“…Introduction: Familial Hypercholesterolemia (FH) is a primarily autosomal dominant condition characterized by markedly elevated low-density lipoprotein-cholesterol (LDL-c) and an increased risk of atherosclerosis and cardiovascular disease (CVD). …”
Get full text

The Prevalence and Diagnostic Ratio of Familial Hypercholesterolemia (FH) and Proportion of Acute Coronary Syndrome in Japanese FH Patients in a Healthcare Record Database Study by Tamio Teramoto, Tomohiro Sawa, Satoshi Iimuro, Hyoe Inomata, Takashi Koshimizu, Iori Sakakibara, Katsutoshi Hiramatsu

“…Background. Familial hypercholesterolemia (FH) is a genetic disorder characterized by high levels of low-density lipoprotein cholesterol (LDL-C). …”
Get full text

Rheumatoid-like hand deformities and aortic valve disease in a 13-year-old girl with homozygous familial hypercholesterolemia: a case report by Anjuman Ara Rahman, Abhijit Datta, Kamal Uddin Ahmed, Anindita Das Barshan, Mohammad Jahid Hasan

Subjects: “…Familial hypercholesterolemia…”
Get full text

Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a) by Frederick Berro Rivera, MD, Sung Whoy Cha, MD, Cruz Linnaeus Louisse, MD, Genquen Philip Carado, MD, John Vincent Magalong, MD, Vincent Anthony Tang, MD, Mary Grace Enriquez, MD, Martha Gulati, MD, MS, Byambaa Enkhmaa, MD, PhD, Neha Pagidipati, MD, MPH, Nishant P. Shah, MD

“…Subgroup analyses revealed consistent treatment effect amongst comparators vs placebo: −27.69% (95% CI: −30.85% to −24.54%, P < 0.001), vs ezetimibe: −24.0% (95% CI: −29.95% to −18.01%, P < 0.001), type of PCSK9i, evolocumab: −29.35% (95% CI: −33.56% to −25.14%, P < 0.001) vs alirocumab: −24.50% (95% CI: −27.96% to −21.04%, P < 0.001), and presence of familial hypercholesterolemia: −25.63% (95% CI: −31.96% to −19.30%, P < 0.001 vs no familial hypercholesterolemia: −27.22%; 95% CI: −30.34% to −24.09%, P < 0.001). …”
Get full text

PCSK9 in T-cell function and the immune response by Yuying Wang, Xiaosheng Fang, Jiarui Liu, Xiao Lv, Kang Lu, Yingxue Lu, Yujie Jiang

“…Abstract Proprotein convertase subtilisin/kexin type 9 (PCSK9) was first reported in 2003 and confirmed to be strongly associated with familial hypercholesterolemia. Small-molecule inhibitors targeting PCSK9 provide an effective and safe method for managing hypercholesterolemia and reducing the cardiovascular risk. …”
Get full text

Clinical and biochemical features of atherogenic hyperlipidemias with different genetic basis: A comprehensive comparative study. by Anastasia V Blokhina, Alexandra I Ershova, Anna V Kiseleva, Evgeniia A Sotnikova, Anastasia A Zharikova, Marija Zaicenoka, Yuri V Vyatkin, Vasily E Ramensky, Vladimir A Kutsenko, Olga A Litinskaya, Maria S Pokrovskaya, Svetlana A Shalnova, Alexey N Meshkov, Oxana M Drapkina

“…We analyzed genetic data from 3374 samples and compared clinical data, lipid levels (low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, triglycerides, and lipoprotein (a)), frequency, age at onset of coronary heart disease (CHD), and the severity of carotid and femoral atherosclerosis (plaque number, maximum stenosis, total stenosis, maximum plaque height, and plaque score) among patients with familial hypercholesterolemia (FH), familial dysbetalipoproteinemia (FD), polygenic hypercholesterolemia (HCL), severe HCL, and those without lipid disorders (n = 324). …”
Get full text